Library — CHDR

Search

Filter

Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study.

Zhuparris A, Maleki G, Koopmans I, Doll RJ, Voet N, Kraaij W, Cohen A, van Brummelen E, De Maeyer JH, Groeneveld GJ

JMIR formative research, 2023 Mar

View publication
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

D. Jennings, S. Huntwork-Rodriguez, M.F.J.M. Vissers, V.M. Daryani, D. Diaz, M.S. Goo, J.J. Chen, R. Maciuca, K. Fraser, O.A. Mabrouk, J. van de Wetering de Rooij, J.A.A.C. Heuberger, G.J. Groeneveld, M. T Borin, A. Cruz-Herranz, D. Graham, K. Scearce-Levie, J. De Vicente, A. G. Henry, P. Chin, C. Ho, M.D. Troyer

Official Journal of the International Parkinson and Movement Disorder Society, 2023 Feb

View publication
Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

Ruijs TQ, Koopmans IW, de Kam ML, van Esdonk MJ, Koltzenburg M, Groeneveld GJ, Heuberger JAAC

Clinical pharmacology and therapeutics, 2022 Nov; 112(5):1008-1019

View publication
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease.

Prins S, de Kam ML, Teunissen CE, Groeneveld GJ

Alzheimer's research & therapy, 2022 Aug; 14(1):106

View publication
A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.

Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, Hsieh E, Groeneveld GJ, Dodart JC

Movement disorders : official journal of the Movement Disorder Society, 2022 Jul; 37(7):1416-1424

View publication
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.

Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C

Clinical and translational science, 2022 Jun

View publication
Modeling buprenorphine reduction of fentanyl-induced respiratory depression.

Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M, Niesters M, Dahan A, Laffont CM

JCI insight, 2022 May

View publication
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.

Thijssen E, den Heijer J, Puibert D, Moss L, Lei M, Hasegawa D, Keum K, Mochel K, Ezzeldin Sharaf M, Alfredson T, Zeng W, van Brummelen E, Naranda T, Groeneveld GJ

Movement disorders : official journal of the Movement Disorder Society, 2022 Apr; 37(4):790-798

View publication
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients.

Thijssen E, den Heijer JM, Puibert D, van Brummelen EMJ, Naranda T, Groeneveld GJ

Parkinsonism & related disorders, 2022 Mar

View publication

«
1
2
3
4
5
6
7
8
...
17
18
»